Funding Details
- Awarder
- Inbox
- Date Award
- March 21, 2018
- Vertical
- Immuno-oncology
- Funding URL
- View Funding Page
- Funding Amount:
-
$125,000,000
Company Info
- Founding Year
- 2015
- Traction
- The company will advance its lead solid tumor program TC-210 targeting mesothelin into the clinic in 2018.
- Founders
- Dr. Patrick Baeuerle
- Company Description
- TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.
- Market
- Cancer therapies
- Location
-
Cambridge,
MA,
USA
- Coinvestors
- 6 Dimensions Capital, Alexandria Real Estate Equities, ArrowMark Partners, Curative Ventures, Haitong International Securities, Hillhouse Capital Group, Lucion Group, Mirae Asset Venture Investment, Redmile Group, Sirona Capital, Syno Capital
Links